RAPS Publishes Regulatory Intelligence 101 Book
Regulatory Intelligence 101 serves as an essential guide to the basics of conducting regulatory intelligence.
Regulatory intelligence (RI), the act of monitoring and analyzing available regulatory information, has become a crucial skill for regulatory professionals working in the pharmaceutical, medical device and biotechnology sectors. Regulatory Intelligence 101, new from the Regulatory Affairs Professionals Society (RAPS) serves as an essential guide to the basics of conducting regulatory intelligence.
Regulatory Intelligence 101 examines available regulatory intelligence tools, both free and those requiring a subscription, and gives tips on how to gatherinformation. Chapters cover everything from the basic regulatory intelligence toolbox to setting up a regulatory intelligence department within a company.
“This book is the culmination of my 14-year love affair with RI, a field that has allowed my affinity for regulatory and love of the profession to shine through,” writes author Meredith Brown-Tuttle, RAC, in the book’s introduction. “It reflects the contributions to the growth and development of RI through the years, and I am proud to have been part of the process.”
According to RAPS’ 2014 Scope of Practice & Compensation Report for the Regulatory Profession, regulatory intelligence currently represents an average of about 6% of regulatory professionals’ job responsibilities.
Regulatory Intelligence 101 is available from the RAPS Store for $44.95 (US) for RAPS members or $54.95 for nonmembers.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
HHS Cancels Moderna Grant for Late-Stage Development of mRNA Vaccine Candidate
June 4th 2025Despite positive results from a Phase I/II trial of its investigational pandemic influenza vaccine, mRNA-1018, Moderna’s award for almost $600 million to accelerate vaccine development will be terminated.
